TG Therapeutics Inc (NASDAQ: TGTX) kicked off on Friday, down -4.98% from the previous trading day, before settling in for the closing price of $33.36. Over the past 52 weeks, TGTX has traded in a range of $12.84-$36.84.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 3133.08% over the past five years. While this was happening, its average annual earnings per share was recorded 22.22%. With a float of $140.52 million, this company’s outstanding shares have now reached $155.78 million.
Let’s look at the performance matrix of the company that is accounted for 264 employees. In terms of profitability, gross margin is 88.22%, operating margin of -0.19%, and the pretax margin is -5.24%.
TG Therapeutics Inc (TGTX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of TG Therapeutics Inc is 9.73%, while institutional ownership is 66.47%. The most recent insider transaction that took place on Jan 03 ’25, was worth 343,443. In this transaction CFO of this company sold 11,337 shares at a rate of $30.29, taking the stock ownership to the 670,632 shares. Before that another transaction happened on Jan 06 ’25, when Company’s CFO sold 10,021 for $28.53, making the entire transaction worth $285,939. This insider now owns 660,611 shares in total.
TG Therapeutics Inc (TGTX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.12 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 22.22% per share during the next fiscal year.
TG Therapeutics Inc (NASDAQ: TGTX) Trading Performance Indicators
Take a look at TG Therapeutics Inc’s (TGTX) current performance indicators. Last quarter, stock had a quick ratio of 3.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.64.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.11, a number that is poised to hit 0.16 in the next quarter and is forecasted to reach 0.97 in one year’s time.
Technical Analysis of TG Therapeutics Inc (TGTX)
TG Therapeutics Inc (NASDAQ: TGTX) saw its 5-day average volume 2.34 million, a negative change from its year-to-date volume of 2.68 million. As of the previous 9 days, the stock’s Stochastic %D was 73.75%. Additionally, its Average True Range was 1.66.
During the past 100 days, TG Therapeutics Inc’s (TGTX) raw stochastic average was set at 67.22%, which indicates a significant increase from 60.76% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.00% in the past 14 days, which was lower than the 63.45% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $31.73, while its 200-day Moving Average is $23.42. Nevertheless, the first resistance level for the watch stands at $33.09 in the near term. At $34.48, the stock is likely to face the second major resistance level. The third major resistance level sits at $35.22. If the price goes on to break the first support level at $30.96, it is likely to go to the next support level at $30.22. Assuming the price breaks the second support level, the third support level stands at $28.83.
TG Therapeutics Inc (NASDAQ: TGTX) Key Stats
The company with the Market Capitalisation of 4.93 billion has total of 155,665K Shares Outstanding. Its annual sales at the moment are 233,660 K in contrast with the sum of 12,670 K annual income. Company’s last quarter sales were recorded 83,880 K and last quarter income was 3,880 K.
